Skip Navigation

Resources

Recommendation
Updated Jan 6, 2010
Video presentation describing the concept behind angiogenesis and the evidence on the anti-angiogenic agent avastin (bevacizumab) in NSCLC.
Recommendation
Updated Jan 6, 2010
One of the core issues in managing advanced NSCLC is second line chemotherapy, which was established as improving survival several years ago. This video presentation provides a brief summary of th... more
Recommendation
Updated Jan 6, 2010
Dr. Sandler recently moved from Vanderbilt to Oregon Health & Science University in Portland where he leads the Division of Hematology and Oncology. He was kind enough to participate in GRACE's N... more
Recommendation
Updated Jan 6, 2010
Dr. George Simon, medical oncologist and Director of the Thoracic Oncology Program at Fox Chase Cancer Center in Philadelphia speaks about molecular factors that are emerging to help us individuali... more
Recommendation
Updated Jan 6, 2010
A video presentation on the topic of Timing the Transition to Maintenance/Second Line Chemotherapy for Advanced NSCLC. We can expect new information to emerge in the coming months and years, but h... more
Acrobat
Uploaded Jan 5, 2010
Over the past several years, many other trials have compared one doublet combination to another, and while there have been a few that showed minor differences, overall these trials have shown that ... more
Acrobat
Uploaded Jan 5, 2010
The guidelines from the American Society for Clinical Oncology (ASCO) for NSCLC start the discussion on how long to continue first-line chemo as follows: “The optimal duration of chemotherapy remai... more
Acrobat
Uploaded Jan 5, 2010
I’ll be extremely interested in new trial results of molecular markers as they emerge. At least for NSCLC, I think we’re on the cusp of re-writing the treatment algorithms for advanced disease...
Acrobat
Uploaded Jan 5, 2010
This work provides a clear indication that we can produce results like we’ve never seen in advanced lung cancer if we can deliver targeted therapies to a targeted, selected population most likely t... more
Acrobat
Uploaded Jan 5, 2010
Although we are all frustrated by the relatively slow pace of progress in lung cancer, there are times when we can look back and feel that we have made a real impact. Six years ago there were no tr... more